| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NCT05131022) | Nurix Therapeutics, Inc. | 2022-04-13 |
| Study of XL114 in Subjects With Non-Hodgkin's Lymphoma (NCT05144347) | Exelixis | 2022-04-12 |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) (NCT05168930) | Dana-Farber Cancer Institute | 2022-02-18 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05105841) | AbbVie | 2021-11-08 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NCT04830137) | Nurix Therapeutics, Inc. | 2021-05-05 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax (NCT04419519) | Memorial Sloan Kettering Cancer Center | 2020-05-13 |
| Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (NCT03788291) | University of Rochester | 2019-03-25 |
| Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) (NCT03702231) | National Heart, Lung, and Blood Institute (NHLBI) | 2018-12-07 |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies (NCT03588598) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-09-07 |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy (NCT03406156) | AbbVie | 2018-08-10 |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (NCT03547115) | MEI Pharma, Inc. | 2018-05-31 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT02966756) | AbbVie | 2017-10-12 |
| A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma (NCT02914938) | MEI Pharma, Inc. | 2016-10-01 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |
| Study Evaluating Venetoclax in Subjects With Hematological Malignancies (NCT02265731) | AbbVie | 2014-09-22 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT01647971) | TG Therapeutics, Inc. | 2012-07-19 |
| A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL (NCT01203930) | Gilead Sciences | 2010-10-01 |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00694590) | Genzyme, a Sanofi Company | 2008-06-01 |